Understanding The Potential Therapeutic Applications of ASS1P13

Target Name: ASS1P13

NCBI ID: G341230

ASS1P13

Other Name(s): argininosuccinate synthetase 1 pseudogene 13 | Argininosuccinate synthetase 1 pseudogene 13 | ASSP13

Understanding The Potential Therapeutic Applications of ASS1P13

Argininosuccinate synthetase (AS) is a key enzyme involved in the production of arginine, a crucial amino acid that plays a vital role in various cellular processes. Mutations in the AS gene have been linked to various cardiovascular and neurological disorders. The pseudogene 13 (ASS1P13) is a non-coding RNA molecule that has been identified in various genomic studies and is annotated as a potential drug target or biomarker. In this article, we will explore the structure, function, and potential therapeutic applications of ASS1P13.

Structure and Expression

ASS1P13 is a small non-coding RNA molecule that is expressed in various tissues and organs, including brain, heart, and liver. It is a member of the AS family, which includes several other enzymes involved in the production of arginine from tryptophan. The AS gene is located on chromosome 16q22 and has a reported mutation rate of about 1% in humans.

The structure of ASS1P13 is of particular interest. It is a 21-kDa protein that consists of 196 amino acid residues. The protein has a molecular weight of 21 kDa and a calculated pI of 4.87. It is expressed in various tissues and organs and is primarily localized to the cytoplasm.

Function

ASS1P13 is involved in the production of arginine from tryptophan, which is a critical precursor for the production of nitric oxide, a well-known cardiovascular regulator. Arginine is a potent vasodilator and has been shown to have anti-inflammatory and anti-apoptotic effects.

In addition to its role in arginine production, ASS1P13 is also involved in the regulation of cell signaling pathways. It has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

Potential Therapeutic Applications

The potential therapeutic applications of ASS1P13 are vast and varied. As a drug target, ASS1P13 could be developed as a therapy for various cardiovascular and neurological disorders, including heart failure, hypertension, and stroke. Arginine production is a critical precursor for the production of nitric oxide, which has been shown to have anti-inflammatory and anti-apoptotic effects. Therefore, inhibiting ASS1P13 activity could be a promising approach to treating cardiovascular disease.

In addition to its potential therapeutic applications, ASS1P13 has also been identified as a potential biomarker for various cardiovascular and neurological disorders. The expression of ASS1P13 is often reduced in patients with cardiovascular and neurological disorders, which could be an indication of reduced arginine production. Therefore, measuring the expression of ASS1P13 could be a useful diagnostic tool for the diagnosis and prognosis of various cardiovascular and neurological disorders.

Conclusion

In conclusion, ASS1P13 is a non-coding RNA molecule that is involved in the production of arginine from tryptophan. It is expressed in various tissues and organs and has been shown to play a role in the regulation of cell signaling pathways, as well as the production of nitric oxide. The potential therapeutic applications of ASS1P13 are vast and varied, including the treatment of cardiovascular and neurological disorders. Further research is needed to fully understand the role of ASS1P13 in these processes and to develop safe and effective therapies based on its properties.

Protein Name: Argininosuccinate Synthetase 1 Pseudogene 13

The "ASS1P13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASS1P13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets